GET-73 is under clinical development by Laboratorio Farmaceutico CT and currently in Phase II for Alcohol Dependence. According to GlobalData, Phase II drugs for Alcohol Dependence does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the GET-73 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GET-73 overview
GET-73 is under development for the treatment of alcohol dependence. The drug candidate is formulated as a capsule, administered through oral route. The drug candidate is a gamma-hydroxybutyrate (GHB) analog. The drug candidate acts by targeting metabotropic glutamate subtype 5 receptor (mGluR5).
See Also:
Laboratorio Farmaceutico CT overview
Laboratorio Pharmaceutic CT Srl (Laboratorio) is a developer of pharmaceutical products. The company’s products offering includes injectable antibiotics, cephalosporins, injectable antibiotics penicillins, antibiotics ampoules, non antibiotics tablets, capsules, suspensions and syrups. Laboratorio headquartered in Sanremo, Italy.
For a complete picture of GET-73’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
